RETATRUTIDE

Retatrutide is a synthetic peptide conjugated to a C20 fatty diacid moiety, classified as a triple hormone receptor agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR) simultaneously. The simultaneous activation of all three receptors produces complementary and synergistic effects on gastric emptying, pancreatic insulin secretion, and energy expenditure — with the glucagon receptor component distinguishing it mechanistically from dual GLP-1/GIP agonists by further promoting hepatic fat oxidation and thermogenesis. Phase 2 clinical trial data reported mean body weight reductions of up to 24.2% at 48 weeks, establishing retatrutide as one of the most potent investigational agents in the obesity and metabolic disease research pipeline. Supplied as lyophilized powder, ≥99% purity. Store at -20°C. Research use only. Not for human consumption.